US Patent No: 5,919,790

Number of patents in Portfolio can not be more than 2000

Hydroxamate inhibitors of interleukin-1.beta. converting enzyme

Stats

See full text
ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula II ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ABBOTT GMBH & CO. KGWIESBADEN113
WARNER-LAMBERT COMPANYMORRIS PLAINS, NJ1990

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Allen, Hamish John Shrewsbury, MA 7 60
Brady, Kenneth Dale Worcester, MA 7 62
Caprathe, Bradley William Livonia, MI 3 33
Galatsis, Paul Ann Arbor, MI 4 25
Gilmore, John Lodge Ann Arbor, MI 2 29
Hays, Sheryl Jeanne Ann Arbor, MI 7 39
Talanian, Robert Vincent Harvard, MA 4 51
Walker, Nigel Dossenheim, DE 9 111
Warmus, Joseph Scott Ann Arbor, MI 9 112

Cited Art Landscape

Patent Info (Count) # Cites Year
 
VERTEX PHARMACEUTICALS INCORPORATED (1)
5,656,627 Inhibitors of interleukin-1.beta. converting enzyme 61 1995

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
ASTRAZENECA AB (9)
7,354,940 2,5-dioxoimidazolidin-4-yl acetamines and analogues as inhibitors of metalloproteinase mmp12 11 2003
7,648,992 Hydantoin derivatives for the treatment of obstructive airway diseases 3 2005
7,700,604 Hydantoin derivatives as metalloproteinase inhibitors 3 2005
7,655,664 Hydantoin derivatives as metalloproteinase inhibitors 3 2005
8,183,251 Hydantoin compounds and pharmaceutical compositions thereof 0 2007
7,666,892 Metalloproteinase inhibitors 3 2008
7,754,750 Metalloproteinase inhibitors 3 2008
7,989,620 Hydantoin derivatives for the treatment of obstructive airway diseases 0 2009
8,153,673 Metalloproteinase inhibitors 0 2010
 
HESKA CORPORATION (4)
6,818,444 Canine and feline proteins, nucleic acid molecules and uses thereof 0 2001
7,205,143 Feline IL-12 single chain nucleic acid molecules 0 2004
7,556,963 Feline IL-18 nucleic acid molecules 0 2006
7,928,197 Feline IL-18 proteins 0 2008
 
IDUN PHARMACEUTICALS, INC. (4)
6,242,422 (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases 36 1998
6,525,024 Inhibitors of the ICE/ced-3 family of cysteine proteases 2 2001
7,157,430 (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases 0 2001
6,969,703 Inhibitors of the ICE/ced-3 family of cysteine proteases 0 2002
 
VERTEX PHARMACEUTICALS INCORPORATED (3)
7,381,827 Processes and intermediates 14 2005
7,834,200 Processes and intermediates 0 2008
8,293,929 Processes and intermediates 0 2010
 
CHILDREN'S MEDICAL CENTER CORPORATION (2)
6,673,828 Analogs of 2-Phthalimidinoglutaric acid 34 1999
7,112,602 Methods of treating undesired angiogenesis with 2-methyl-EM-138 7 2003
 
SMITHKLINE BEECHAM CORPORATION (1)
6,420,424 CCR-3 receptor antagonists 1 2000